News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
695,512 Results
Type
Article (39537)
Company Profile (327)
Press Release (655648)
Section
Business (206278)
Career Advice (2009)
Deals (35691)
Drug Delivery (89)
Drug Development (81917)
Employer Resources (170)
FDA (16142)
Job Trends (14944)
News (348490)
Policy (32655)
Tag
Academia (2538)
Alliances (49834)
Alzheimer's disease (1263)
Approvals (16094)
Artificial intelligence (144)
Bankruptcy (352)
Best Places to Work (11682)
Biotechnology (232)
Breast cancer (189)
Cancer (1372)
Cardiovascular disease (112)
Career advice (1674)
Cell therapy (283)
Clinical research (65560)
Collaboration (490)
Compensation (264)
COVID-19 (2551)
C-suite (110)
Data (1396)
Diabetes (172)
Diagnostics (6181)
Earnings (85809)
Employer resources (148)
Events (112098)
Executive appointments (397)
FDA (16812)
Funding (427)
Gene therapy (195)
GLP-1 (606)
Government (4349)
Healthcare (18739)
Infectious disease (2643)
Inflammatory bowel disease (111)
Interviews (313)
IPO (16522)
Job creations (3672)
Job search strategy (1427)
Layoffs (422)
Legal (7887)
Lung cancer (197)
Lymphoma (98)
Manufacturing (207)
Medical device (13221)
Medtech (13226)
Mergers & acquisitions (19330)
Metabolic disorders (454)
Neuroscience (1587)
NextGen Class of 2024 (6526)
Non-profit (4481)
Northern California (1697)
Obesity (259)
Opinion (183)
Patents (117)
People (57131)
Phase I (20419)
Phase II (28922)
Phase III (21441)
Pipeline (514)
Postmarket research (2566)
Preclinical (8677)
Radiopharmaceuticals (244)
Rare diseases (260)
Real estate (5979)
Regulatory (21832)
Research institute (2323)
Resumes & cover letters (349)
Southern California (1465)
Startups (3608)
United States (15302)
Vaccines (566)
Weight loss (182)
Date
Last 7 days (584)
Last 30 days (2266)
Last 365 days (35511)
2024 (35351)
2023 (40473)
2022 (51632)
2021 (56244)
2020 (54473)
2019 (46901)
2018 (35314)
2017 (32507)
2016 (31947)
2015 (38017)
2014 (31842)
2013 (26766)
2012 (28940)
2011 (29608)
2010 (27666)
Location
Africa (723)
Arizona (197)
Asia (38196)
Australia (6199)
California (3829)
Canada (1453)
China (308)
Colorado (173)
Connecticut (178)
Europe (82571)
Florida (538)
Georgia (135)
Illinois (386)
Indiana (224)
Maryland (632)
Massachusetts (2999)
Michigan (172)
Minnesota (292)
New Jersey (1112)
New York (1086)
North Carolina (786)
Northern California (1697)
Ohio (146)
Pennsylvania (926)
South America (1104)
Southern California (1465)
Texas (554)
Utah (108)
Washington State (403)
695,512 Results for "regenerx biopharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioCapital
RegeneRx To Extend Consent Solicitation Vote
RegeneRx Biopharmaceuticals, Inc. announced that, pursuant to the company’s consent solicitation dated July 11, 2023, holders of 48.5% of the Company’s outstanding stock have voted to date, with 94% voting in favor of the proposed reverse stock split.
August 1, 2023
·
2 min read
Deals
RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations
RegeneRx Biopharmaceuticals, Inc. announced that it has today effected a 1-for-100 reverse split in the outstanding shares of Common Stock of the Company and has filed the requisite Form 15 to suspend and terminate the Company’s continued obligations to file reports with the SEC pursuant to Sections 13(d) and 15(d) of the Securities Exchange Act of 1934, as amended.
August 15, 2023
·
2 min read
BioCapital
RegeneRx Issues Letter To Stockholders - April 11, 2023
RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair, and regeneration, has issued a Letter to Stockholders updating its ongoing operating strategy.
April 11, 2023
·
2 min read
BioCapital
RegeneRx Receives Stockholder Approval for Reverse Stock Split - August 07, 2023
RegeneRx Biopharmaceuticals, Inc. announced that, pursuant to the company’s consent solicitation dated July 11, 2023, it has received consents as of August 3, 2023 from the holders of 51.07% of the Company’s Common Stock in favor of the proposed reverse stock split, which is a prerequisite to allowing the Company to suspend its public reporting obligations under the Securities Exchange Act of 1934 and become a non-reporting, privately held company.
August 7, 2023
·
2 min read
BioMidwest
Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024
Navidea Biopharmaceuticals, Inc., a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced it will be hosting a virtual meeting of its stockholders at 1pm ET on Monday, July 8th, 2024.
June 20, 2024
·
5 min read
BioCapital
RegeneRx Issues 2022 Letter To Stockholders
RegeneRx Biopharmaceuticals, Inc. has issued a Letter to Stockholders updating development of product candidates.
August 22, 2022
·
2 min read
Deals
RegeneRx Licensee Acquired by Korean Biopharmaceutical Group
RegeneRx Biopharmaceuticals, Inc. today announced that GtreeBNT, the licensee for several RegeneRx products, is being acquired by HLB Group, a Korean company
September 27, 2021
·
3 min read
Press Releases
Angitia Biopharmaceuticals Announces $120 Million Series C Financing
December 11, 2024
·
4 min read
BioCapital
RegeneRx Biopharmaceuticals, Inc. Announces $2 Million Private Placement
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“RegeneRx”), today announced that it has entered into a definitive agreement with certain institutional and accredited investors, including certain directors and officers of the Company, in connection with a private placement of up to $2,000,000 of shares of its common stock and warrants at a purchase price of $0.20 per share and accompanying warrants
June 28, 2021
·
3 min read
BioMidwest
Provectus Biopharmaceuticals Announces Investor Webinar for 2024 Annual Meeting of Stockholders
Provectus Biopharmaceuticals, Inc. announced that its 2024 annual stockholder meeting, including meeting activities and a company update, will be accessible by Zoom Webinar.
June 13, 2024
·
5 min read
1 of 69,552
Next